Unicycive Therapeutics (UNCY) Cash & Current Investments (2021 - 2026)

Unicycive Therapeutics (UNCY) has 6 years of Cash & Current Investments data on file, last reported at $54.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 176.12% year-over-year to $54.6 million; the trailing twelve-month figure through Mar 2026 stood at $54.6 million (up 176.12% YoY), and the FY2025 full-year result was $41.3 million, up 57.86% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $54.6 million, up from $41.3 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $54.6 million in Q1 2026 and bottomed at $455000.0 in Q4 2022.
• The 5-year median for Cash & Current Investments is $22.3 million (2025), against an average of $25.2 million.
• Peak annual rise in Cash & Current Investments reached 1057200.0% in 2022, while the deepest fall reached 97.26% in 2022.
• A 5-year view of Cash & Current Investments shows it stood at $455000.0 in 2022, then soared by 2032.09% to $9.7 million in 2023, then surged by 169.48% to $26.1 million in 2024, then soared by 57.86% to $41.3 million in 2025, then jumped by 32.27% to $54.6 million in 2026.
• The last three Cash & Current Investments figures came in at $54.6 million (Q1 2026), $41.3 million (Q4 2025), and $42.7 million (Q3 2025), per Business Quant data.

Peer Comparison